Literature DB >> 17611006

G6PD deficiency: the genotype-phenotype association.

Philip J Mason1, José M Bautista, Florinda Gilsanz.   

Abstract

Deficiency of glucose-6-phosphate dehydrogenase is a very common X-linked genetic disorder though most deficient people are asymptomatic. A number of different G6PD variants have reached polymorphic frequencies in different parts of the world due to the relative protection they confer against malaria infection. People, usually males, with deficient alleles are susceptible to neonatal jaundice, and acute hemolytic anemia, usually during infection, after treatment with certain drugs or after eating fava beans. Very rarely de novo mutations can arise causing the more severe condition of chronic nonspherocytic hemolytic anemia. Altogether 160 different mutations have been described. The majority of mutations cause red cell enzyme deficiency by decreasing enzyme stability. The polymorphic mutations affect amino acid residues throughout the enzyme and decrease the stability of the enzyme in the red cell, possibly by disturbing protein folding. The severe mutations mostly affect residues at the dimer interface or those that interact with a structural NADP molecule that stabilizes the enzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17611006     DOI: 10.1016/j.blre.2007.05.002

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  91 in total

Review 1.  Population genetics of malaria resistance in humans.

Authors:  P W Hedrick
Journal:  Heredity (Edinb)       Date:  2011-03-23       Impact factor: 3.821

2.  Regulation of G6PD acetylation by SIRT2 and KAT9 modulates NADPH homeostasis and cell survival during oxidative stress.

Authors:  Yi-Ping Wang; Li-Sha Zhou; Yu-Zheng Zhao; Shi-Wen Wang; Lei-Lei Chen; Li-Xia Liu; Zhi-Qiang Ling; Fu-Jun Hu; Yi-Ping Sun; Jing-Ye Zhang; Chen Yang; Yi Yang; Yue Xiong; Kun-Liang Guan; Dan Ye
Journal:  EMBO J       Date:  2014-04-25       Impact factor: 11.598

3.  Life and Death of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficient Erythrocytes - Role of Redox Stress and Band 3 Modifications.

Authors:  Paolo Arese; Valentina Gallo; Antonella Pantaleo; Franco Turrini
Journal:  Transfus Med Hemother       Date:  2012-09-17       Impact factor: 3.747

4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.

Authors:  M V Relling; E M McDonagh; T Chang; K E Caudle; H L McLeod; C E Haidar; T Klein; L Luzzatto
Journal:  Clin Pharmacol Ther       Date:  2014-05-02       Impact factor: 6.875

5.  Biological impact of α genes, β haplotypes, and G6PD activity in sickle cell anemia at baseline and with hydroxyurea.

Authors:  Françoise Bernaudin; Cécile Arnaud; Annie Kamdem; Isabelle Hau; Françoise Lelong; Ralph Epaud; Corinne Pondarré; Serge Pissard
Journal:  Blood Adv       Date:  2018-03-27

6.  Glucose-6-phosphate dehydrogenase deficiency in Tunisia: molecular data and phenotype-genotype association.

Authors:  N Laouini; A Bibi; H Ammar; K Kazdaghli; F Ouali; R Othmani; S Amdouni; S Haloui; C A Sahli; L Jouini; S Hadj Fredj; H Siala; N Ben Romdhane; N E Toumi; S Fattoum; T Messsaoud
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

7.  A novel G6PD mutation leading to chronic hemolytic anemia.

Authors:  Jenny McDade; Tatiana Abramova; Nicole Mortier; Thad Howard; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

8.  Relating mutant genotype to phenotype via quantitative behavior of the NADPH redox cycle in human erythrocytes.

Authors:  Pedro M B M Coelho; Armindo Salvador; Michael A Savageau
Journal:  PLoS One       Date:  2010-09-28       Impact factor: 3.240

Review 9.  Pharmacogenetics in heart failure: how it will shape the future.

Authors:  Eman Hamad; Arthur M Feldman
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

10.  Impact of the method of G6PD deficiency assessment on genetic association studies of malaria susceptibility.

Authors:  Marla K Johnson; Tamara D Clark; Denise Njama-Meya; Philip J Rosenthal; Sunil Parikh
Journal:  PLoS One       Date:  2009-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.